石四药集团:短期收入、利润承压 长期制剂业务放量可期

国信证券
08 May

受盐酸溴己新事件影响,2024 年公司整体业绩承压。2024 年公司实现营收57.73 亿港元(-10.7%),归母净利润10.61 亿港元(-19.5%),受盐酸溴己新退货影响,公司收入、利润均出现一定幅度下滑。2024 年全年毛利率50.4%(-5.6pp),净利率18.4%(-2.0pp)。费率控制良好,销售费用率19.8%(-3.9pp),管理费用率5.2%(+0.41pp),财务费用率...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10